Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.42 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.42 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248544 | 0.91 | AKR1C1 (0.64) | AKR1C1HSD11B1HDAC4KMT2AMEN1 | |
| SCHEMBL6349290 | 0.91 | AKR1C1 (0.70) | AKR1C1HSD11B1HDAC4KMT2AMEN1 | |
| SCHEMBL1061631 | 0.90 | AKR1C1 (0.68) | AKR1C1HSD11B1HDAC4KMT2AMEN1 | |
| SCHEMBL19335064 | 0.90 | AKR1C1 (0.68) | AKR1C1HSD11B1HDAC4KMT2AMEN1 | |
| SCHEMBL19249604 | 0.90 | AKR1C1 (0.68) | AKR1C1HSD11B1HDAC4KMT2AMEN1 | |
| SCHEMBL19335085 | 0.90 | AKR1C1 (0.68) | AKR1C1HSD11B1HDAC4KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL11114113 | 0.85 | OPRM1 (0.56) | AKR1C1HSD11B1HDAC4HDAC1 | |
| SCHEMBL5172596 | 0.83 | KMT2A (0.53) | AKR1C1HSD11B1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4917642 | 0.83 | OPRM1 (0.61) | AKR1C1HSD11B1 | |
| SCHEMBL3116138 | 0.81 | AKR1C1 (0.61) | AKR1C1HSD11B1HDAC4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113061098-B | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-113061098-A | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2021-07-02 | — | — | CN | disclosed |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| CN-105732624-B | The preparation method and its usage of pyrroles [4,3,2-de] quinoline -2 (1H) -one class BRD4 protein inhibitor | 中国药科大学 | 2019-08-02 | — | — | CN | disclosed |
| EP-3504213-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2018-08-09 | — | — | US | disclosed |
| EP-1079830-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | Avanir Pharmaceuticals (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
| WO-1999061020-A1 | BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE | AVANIR PHARMACEUTICALS (US) | 1999-12-02 | — | — | WO | disclosed |
| CN-1226886-A | Arylcycloalkane carboxylic acid esters, their use, pharmaceutical compositions and process for their preparation | PHARMACIA & UPJOHN AB (SE) | 1999-08-25 | — | — | CN | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998046599-A1 | NOVEL CARBOXAMIDES AS PLATELET AGGREGATION INHIBITORS | J. URIACH & CIA. S.A. (ES) | 1998-10-22 | — | — | WO | disclosed |
| US-5723475-A | Arylpiperidine and arylpiperazine derivatives and medicament containing the same | SUNTORY LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
| EP-0757986-A1 | ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | AKR1C1 4292/4885HSD11B1 4674/4885HDAC4 2394/4885 |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | AKR1C1 2194/4885HSD11B1 1546/4885HDAC4 3119/4885 |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | BTK, SYK, LCK | AKR1C1 1586/4885HSD11B1 1134/4885HDAC4 1949/4885 |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | AKR1C1 4261/4885HSD11B1 4687/4885HDAC4 2372/4885 |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | AKR1C1 4261/4885HSD11B1 4687/4885HDAC4 2372/4885 |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | AKR1C1 4292/4885HSD11B1 4674/4885HDAC4 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.